Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHCNASDAQ:CNTANASDAQ:INDVNASDAQ:TRML On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Companies$4.57-2.5%$5.46$3.96▼$9.85$1.65B0.342.59 million shs402,795 shsCNTACentessa Pharmaceuticals$12.75-3.4%$13.31$7.75▼$19.09$1.70B1.53638,835 shs442,052 shsINDVIndivior$11.32-1.1%$10.18$7.33▼$18.59$1.56B0.981.01 million shs245,732 shsTRMLTourmaline Bio$15.07-7.0%$15.61$11.56▼$29.79$386.17M2.11275,642 shs123,055 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Companies+0.65%0.00%-8.88%-28.63%-28.04%CNTACentessa Pharmaceuticals+7.67%+5.94%+7.32%-17.03%+51.38%INDVIndivior-2.05%+2.23%+26.97%+4.88%-33.06%TRMLTourmaline Bio-2.59%+4.25%+1.19%+28.57%+11.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHCBausch Health Companies4.222 of 5 stars2.92.00.04.03.51.71.9CNTACentessa Pharmaceuticals3.6101 of 5 stars4.51.00.00.04.03.30.6INDVIndivior3.3235 of 5 stars3.63.00.00.02.61.71.9TRMLTourmaline Bio2.0714 of 5 stars3.51.00.00.03.22.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Companies 1.86Reduce$7.4262.47% UpsideCNTACentessa Pharmaceuticals 3.00Buy$27.00111.71% UpsideINDVIndivior 3.25Buy$15.0032.57% UpsideTRMLTourmaline Bio 3.00Buy$49.33227.47% UpsideCurrent Analyst Ratings BreakdownLatest TRML, BHC, CNTA, and INDV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025CNTACentessa PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform ➝ Outperform$6.005/8/2025CNTACentessa PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.005/5/2025TRMLTourmaline BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.005/5/2025TRMLTourmaline BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.005/2/2025BHCBausch Health CompaniesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$8.50 ➝ $10.004/23/2025TRMLTourmaline BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$70.004/7/2025BHCBausch Health CompaniesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform$9.00 ➝ $8.503/31/2025CNTACentessa PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$38.003/26/2025CNTACentessa PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.003/14/2025TRMLTourmaline BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$42.00 ➝ $43.003/14/2025TRMLTourmaline BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$49.00 ➝ $50.00(Data available from 5/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Companies$9.73B0.17$4.86 per share0.94($0.89) per share-5.13CNTACentessa Pharmaceuticals$15M113.59N/AN/A$2.42 per share5.27INDVIndivior$1.17B1.33$2.29 per share4.94N/A∞TRMLTourmaline BioN/AN/AN/AN/A$10.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Companies-$46M-$0.11N/A0.980.37-0.48%-577.82%5.24%7/30/2025 (Estimated)CNTACentessa Pharmaceuticals-$151.09M-$1.81N/AN/AN/AN/A-52.13%-38.01%N/AINDVIndivior$2M-$0.31N/A6.62N/A-3.96%-241.73%15.09%7/24/2025 (Estimated)TRMLTourmaline Bio-$42.12M-$3.21N/AN/AN/AN/A-20.97%-20.56%N/ALatest TRML, BHC, CNTA, and INDV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025CNTACentessa Pharmaceuticals-$0.35-$0.20+$0.15-$0.20N/AN/A5/2/2025Q1 2025TRMLTourmaline Bio-$0.91-$0.89+$0.02-$0.89N/AN/A4/24/2025Q1 2025INDVIndivior$0.22$0.41+$0.19$0.38$240.13 million$266.00 million3/24/2025Q4 2024CNTACentessa Pharmaceuticals-$0.38-$0.34+$0.04-$0.84N/AN/A3/13/2025Q4 2024TRMLTourmaline Bio-$0.91-$0.86+$0.05-$0.86N/A$0.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CompaniesN/AN/AN/AN/AN/ACNTACentessa PharmaceuticalsN/AN/AN/AN/AN/AINDVIndiviorN/AN/AN/AN/AN/ATRMLTourmaline BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health CompaniesN/A0.860.62CNTACentessa Pharmaceuticals0.1521.5221.52INDVIndiviorN/A0.830.65TRMLTourmaline BioN/A40.3340.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Companies78.65%CNTACentessa Pharmaceuticals82.01%INDVIndivior60.33%TRMLTourmaline Bio91.89%Insider OwnershipCompanyInsider OwnershipBHCBausch Health Companies8.05%CNTACentessa Pharmaceuticals7.09%INDVIndiviorN/ATRMLTourmaline Bio11.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Companies19,900362.40 million338.06 millionOptionableCNTACentessa Pharmaceuticals200133.60 million116.56 millionOptionableINDVIndivior1,164137.88 millionN/ANot OptionableTRMLTourmaline Bio4425.69 million22.82 millionOptionableTRML, BHC, CNTA, and INDV HeadlinesRecent News About These CompaniesTourmaline Bio, Inc. (NASDAQ:TRML) Stake Increased by Velan Capital Investment Management LPMay 21 at 8:23 AM | marketbeat.comTourmaline touts cardiovascular potential of former Pfizer antibody after phase 2 kidney disease winMay 21 at 12:18 AM | fiercebiotech.comTourmaline Bio posts mid-stage data for anti-inflammatory agentMay 21 at 12:18 AM | msn.comTourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 InhibitionMay 20 at 5:08 PM | seekingalpha.comTourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025May 19 at 4:05 PM | globenewswire.comContrasting Exelixis (NASDAQ:EXEL) & Tourmaline Bio (NASDAQ:TRML)May 16, 2025 | americanbankingnews.comAnalysts Set Expectations for Tourmaline Bio FY2025 EarningsMay 10, 2025 | marketbeat.comLeerink Partnrs Comments on Tourmaline Bio FY2025 EarningsMay 10, 2025 | marketbeat.comBrokers Set Expectations for Tourmaline Bio FY2025 EarningsMay 9, 2025 | marketbeat.comQ2 EPS Estimates for Tourmaline Bio Decreased by AnalystMay 9, 2025 | marketbeat.comLeerink Partnrs Weighs in on Tourmaline Bio Q2 EarningsMay 9, 2025 | marketbeat.comAlyeska Investment Group L.P. Lowers Position in Tourmaline Bio, Inc. (NASDAQ:TRML)May 9, 2025 | marketbeat.comHC Wainwright Weighs in on Tourmaline Bio Q2 EarningsMay 8, 2025 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Receives "Buy" Rating from HC WainwrightMay 7, 2025 | marketbeat.comTourmaline Bio's (TRML) "Buy" Rating Reiterated at Chardan CapitalMay 7, 2025 | marketbeat.comTourmaline Bio (TRML) Expected to Announce Earnings on MondayMay 7, 2025 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Shares Purchased by Barclays PLCMay 7, 2025 | marketbeat.comTourmaline Bio Reports Q1 2025 Financial ResultsMay 7, 2025 | tipranks.comSusquehanna Fundamental Investments LLC Invests $467,000 in Tourmaline Bio, Inc. (NASDAQ:TRML)May 6, 2025 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Rating of "Buy" from BrokeragesMay 6, 2025 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Issues Earnings ResultsMay 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTRML, BHC, CNTA, and INDV Company DescriptionsBausch Health Companies NYSE:BHC$4.57 -0.12 (-2.46%) As of 01:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Centessa Pharmaceuticals NASDAQ:CNTA$12.75 -0.45 (-3.39%) As of 01:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.Indivior NASDAQ:INDV$11.32 -0.13 (-1.09%) As of 01:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Tourmaline Bio NASDAQ:TRML$15.06 -1.14 (-7.01%) As of 01:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palo Alto Networks: Buy The Dip, Long-Term Tailwinds Ahead Lowe’s Stock Uptrend Can Continue for These 2 Reasons CrowdStrike Near Breakout: Is Now the Time to Buy? Rivian Stock Below $20: Charging Up or in the Breakdown Lane? Viking Holdings Posts Strong Q1, Eyes Growth Ahead 2 Reasons Netflix’s 40% Rally Is Far From Over Qualcomm’s Re-Entry Into the CPU Market May Not Be Enough Applied Digital's Strategic AI Play Gains Momentum Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
